Patent EP0505749A2 successfully refreshed from Google Patents.
EP0505749A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Monoclonal antibodies directed to activated endothelial cells and their therapeutic and diagnostic use
Assignee: Otsuka Pharmaceutical Co Ltd
•
Filing: 1992-02-25
•
Granted: —
•
Expires: 2012-02-25
Abstract
Abstract Monoclonal antibodies are produced that bind specifically to IL-1 activated endothelial cells. Antigens to which the monoclonal antibodies specifically bind are identified. The monoclonal antibodies and antigens are useful in a medicament and method for treating inflammatory responses associated with activated endothelial cells, and for diagnosing inflammatory responses. A cDNA sequence that codes for antigen 1E7/2G7 and the CD4<+> ELAM ligand are also described.
Inventors
- 👤 Walter c/o Otsuka America Newman
- 👤 Yoji c/o University of Michigan Shimizu
- 👤 Stephen J. Shaw
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-25 09:29
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; A; A61; A61P; A61P29/00; A61P37/00; C07K14/00; C07K14/435; C07K14/705; C07K14/7056; C07K14/70564; A61K; A61K38/00
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
63 words
A method of regulating immune responses comprising binding to immune cells, endothelial cells or both, (a) an antibody, or binding site-containing fragment thereof, that specifically binds to an ELAM molecule; and (b) at least one antibody, or binding site-containing fragment thereof, that specifically binds to a molecule selected from the group consisting of VCAM, ELAM, ICAM, VCAM ligand, ELAM ligand and ICAM ligand.
Claim 2
Dependent Claim
14 words
The method of claim 1, wherein said immune cells are T-cells, granulocytes or monocytes.
Claim 3
Dependent Claim
11 words
The method of claim 2, wherein said immune cells are T-cells.
Claim 4
Dependent Claim
11 words
The method of claim 3, wherein said T-cells are CD4⁺ cells.
Claim 5
Dependent Claim
12 words
The method of claim 4, wherein said CD4⁺ cells are memory cells.
Claim 6
Dependent Claim
41 words
The method of claim 1, wherein said binding site-containing fragment of said antibody (a) or one of said at least one antibody (b), and said binding site-containing fragment of one of said at least one antibody (b) comprise a bispecific antibody.
Claim 7
Dependent Claim
25 words
The method of claim 1, wherein one of said at least one antibody (b), or binding site-containing fragment thereof, specifically binds to said VCAM molecule.
Claim 8
Dependent Claim
26 words
The method of claim 7, wherein a second of said at least one antibody (b), or binding site-containg fragment thereof, specifically binds to said ICAM molecule.
Claim 9
Dependent Claim
21 words
The method of claim 1, wherein said antibodies, or binding site-containing fragments thereof, do not specifically bind to the same molecule.
Claim 10
Dependent Claim
52 words
The method of claim 9, wherein one of said antibodies, or binding site-containing fragment thereof, specifically binds to an endothelial cell molecule and another of said antibodies, or binding site-containing fragment thereof, specifically binds to an immune cell molecule wherein said immune cell molecule is a ligand of said endothelial cell molecule.
Claim 11
Dependent Claim
22 words
The method of claim 1 which comprises antibody 7A9, or binding site-containing fragment thereof, or antibody 2G7, or binding site-containing fragment thereof.
Claim 12
Dependent Claim
39 words
The method of claim 11 which further comprises an antibody, or binding site-containing fragment thereof, that specifically binds to said VCAM ligand molecule or an antibody, or binding site-containing fragment thereof, that specifically binds to said ELAM ligand molecule.
Claim 13
Dependent Claim
84 words
A medicament associated with immune cells and endothelial cells comprising: (A) an antibody, or binding site-containing fragment thereof, or pharmaceutically acceptable salts of said antibody or fragment, that specifically binds to an ELAM molecule; (B) at least one antibody, or binding site-containing fragment thereof, or pharmaceutically acceptable salts of said antibody or fragment, that specifically binds to a molecule selected from the group consisting of VCAM, ELAM, ICAM, VCAM ligand, ELAM ligand and ICAM ligand; and (C) a pharmaceutically acceptable carrier, diluent or excipient.
Claim 14
Dependent Claim
41 words
The medicament of claim 13, wherein said binding site-containing fragment of said antibody (a) or one of said at least one antibody (b), and said binding site-containing fragment of one of said at least one antibody (b) comprise a bispecific antibody.
Claim 15
Dependent Claim
23 words
The medicament of claim 13 which comprises an antibody, or binding site-containing fragment thereof, that specifically binds to a molecule on T cells.
Claim 16
Dependent Claim
22 words
The medicament of claim 13 which comprises an antibody, or binding site-containing fragment thereof, that specifically binds to a molecule on granulocytes.
Claim 17
Dependent Claim
25 words
The medicament of claim 13, wherein one of said at least one antibody (b), or binding site-containing fragment thereof, specifically binds to said VCAM molecule.
Claim 18
Dependent Claim
26 words
The medicament of claim 17, wherein a second of said at least one antibody (b), or binding site-containing fragment thereof, specifically binds to said ICAM molecule.
Claim 19
Dependent Claim
21 words
The medicament of claim 13, wherein said antibodies, or binding site-containing fragments thereof, do not specifically bind to the same molecule.
Claim 20
Dependent Claim
52 words
The medicament of claim 19, wherein one of said antibodies, or binding site-containing fragment thereof, specifically binds to an endothelial cell molecule and another of said antibodies, or binding site-containing fragment thereof, specifically binds to an immune cell molecule wherein said immune cell molecule is a ligand of said endothelial cell molecule.
Claim 21
Dependent Claim
22 words
The medicament of claim 13 which comprises antibody 7A9, or binding site-containing fragment thereof, or antibody 2G7, or binding site-containing fragment thereof.
Claim 22
Dependent Claim
39 words
The medicament of claim 21 which further comprises an antibody, or binding site-containing fragment thereof, that specifically binds to said VCAM ligand molecule or an antibody, or binding site-containing fragment thereof, that specifically binds to said ELAM ligand molecule.
Claim 23
Dependent Claim
22 words
The use of the antibody as defined in claims 13 to 22 for the preparation of a medicament to combat inflammatory diseases.
Claim 24
Dependent Claim
13 words
The use according to claim 23 to combat acute and chronic inflammatory diseases.
Claim 25
Dependent Claim
33 words
The use of the antibody as defined in claims 13 to 22 for the preparation of a medicament suitable in treatment for controlling immune responses by modulating CD4⁺ T-cell reactivity with endothelial cells.
Claim 26
Dependent Claim
16 words
The use of the antibody as defined in claims 13 to 22 to detect inflammatory responses.
Claim 27
Dependent Claim
18 words
The use according to claim 26, wherein these inflammatory responses are early graft rejection, subclinical infection, and vasculitis.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.